Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keverprazan Dual Therapy for H. Pylori
NCT06412640Phase 4Not yet recruiting
- Sponsor
- Nanjing First Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of keverprazan in Helicobacter pylori infection, sponsored by Nanjing First Hospital. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06412640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412640.